MAP2K7 and melanoma: It is documented that after 2 weeks of treatment with BRAF and MEK inhibitors, melanoma cells have been able to downregulate melanoma differentiation antigens (MDA) surface expression, decrease T cell activity, and surface display of increase immune checkpoint inhibitory receptors [64,65].